Clinical Trial Update: Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TRP-8802 (psilocybin) for binge eating disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Binge Eating Disorder

Drugs mentioned

• TRP-8802 (psilocybin)

Snippet

Sponsor: TRYP Therapeutics | Conditions: Binge Eating Disorder | Phase 2 | Status: COMPLETED